ARTICLE | Company News
BTG, LeukoSite deal
March 15, 1999 8:00 AM UTC
LKST received an exclusive license to BTG's anti-CD3 humanized aglycosylated antibody to treat transplant rejection. BTG received an upfront payment and is eligible for milestones and royalties. ...